Filing Details
- Accession Number:
- 0001209191-20-031881
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-05-22 20:00:40
- Reporting Period:
- 2020-05-20
- Accepted Time:
- 2020-05-22 20:00:40
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 873303 | Sarepta Therapeutics Inc. | SRPT | Pharmaceutical Preparations (2834) | 930797222 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1492766 | Rudolf Lennart Hans Wigzell | 215 First Street, Suite 415 Cambridge MA 02142 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-05-20 | 5,000 | $10.08 | 18,792 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-05-20 | 2,100 | $149.62 | 16,692 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-20 | 2,046 | $151.22 | 14,646 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-20 | 854 | $151.77 | 13,792 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Oprion (right to buy) | Disposition | 2020-05-20 | 5,000 | $0.00 | 5,000 | $10.08 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2013-08-23 | 2022-08-23 | No | 4 | M | Direct |
Footnotes
- The shares were sold in transactions at prices ranging from $149.11 to $149.89, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The shares were sold in transactions at prices ranging from $150.62 to $151.62, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The shares were sold in transactions at prices ranging from $151.67 to $151.75, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Billionaire Hedge Funds
